Customer Concentration

12 Months Ended

Dec. 31, 2019

Concentration Risk Disclosure [Text Block]

Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:



	Year Ended December 31,
(in thousands)	2019⁽¹⁾		2018⁽¹⁾		2017⁽¹⁾

kaléo	—	%	—	%	16	%
Merck	—	%	—	%	21	%
Biogen	—	%	14	%	40	%
LENSAR	100	%	77	%	17	%

________________

⁽¹⁾The amounts above exclude product sales in our Pharmaceutical segment and royalty rights classified as held for sale in the Income Generating Assets segment, each of which is included in the Statements of Operations as (Loss) income from discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale, for additional information.

Total revenues by geographic area are based on the country of domicile of the counterparty to the agreement are as follows:



	Year Ended December 31,
(in thousands)	2019		2018		2017

United States	$	15,151	$	21,434	$	83,143
Europe	3,438		2,451		2,732
Rest of world	12,117		8,143		5,424
Total revenues ⁽¹⁾	$	30,706	$	32,028	$	91,299

________________

⁽¹⁾The amounts above exclude product sales in our Pharmaceutical segment and royalty rights held for sale in the Income Generating Assets segment, each of which is included in the Statements of Operations as (Loss) income from discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale, for additional information.

One customer accounted for more than 10% of accounts receivable, net as of December 31, 2019. A separate customer accounted for more than 10% of accounts receivable, net as of December 31, 2018.